Skip to content

EDEN study

Effects of D-alanine on Lipid metabolism in patients with CKD - EDEN study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051240262
Enrollment
20
Registered
2025-02-05
Start date
2025-06-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD with Dyslipidemia

Interventions

Intake of D-alanine

Sponsors

Matsui Masaru
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Who aged 18 years or older at the time of consent 2) Who meet either and or both of the following renal criteria within 60 days before enrollment A) eGFR less than 60mL/min/1.73m2 B) Urinary protein/urinary creatine ratio of 0.15 g/gcre or higher 3) Who have an elevated fasting TG/HDL ratio within 60 days before enrollment(2.967 or higher for men, 2.237 or higher for women) 4) Whose treatment for diabetes, hypertension or dyslipidemia (including dietary and exercise therapy) has not changed within 90 days before obtaining consent

Exclusion criteria

Exclusion criteria: 1) Who have taken fibrates, selective PPARalpha modulators, or n3-polyunsaturated fatty acids within 90 days before obtaining consent 2) With TG levels of 500 mg/dL or higher 3) Who are pregnant, breastfeeding, or planning to be pregnant during study period 4) With poorly controlled(glycated A1c(NGSP) > 10%) 5) With uncontrolled hypertension despite optimal antihypertensive agents(either systolic blood pressure >=180 mmHg or diastolic blood pressure >=110mmHg) 6) With severe liver dysfunction(AST(GOT) or ALT(GPT) >=100 IU/L) 7) With severe renal dysfunction(eGFR < 30 mL/min/1.73m2) 8) With a concurrent malignancy 9) Who participated in another clinical trial (interventional study) within 90 days prior to the study drug administration 10) Whom the principal investigator or sub-investigator deems inappropriate for study participation

Design outcomes

Primary

MeasureTime frame
Changes in serum TG/HDL ratio 4 weeks after administration of D-alanine

Secondary

MeasureTime frame
Changes in TG, HDL, LDL, AST, ALT, systolic blood pressure, diastolic pressure, urinary protein (Uprot/Ucre), eGFR and body weight

Contacts

Public ContactMasaru Matsui

Nara Medical University Hospital

masaru@naramed-u.ac.jp+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026